Case report reveals atypical diagnosis of metastatic grade II pancreatic neuroendocrine tumor, highlighting challenges of recognizing symptoms and the need for targeted therapies.
Key Points
The patient presented with weight loss and vague abdominal symptoms, leading to significant anemia and diagnosis of metastatic disease.
A liver biopsy confirmed a moderately differentiated, grade II neuroendocrine tumor, emphasizing the importance of histopathological evaluation.
Treatment involved initiating intramuscular octreotide, while the patient was provided with palliative care upon discharge.
Timely diagnosis, integration of molecular screening, and access to targeted therapies are crucial for improving patient outcomes.